Insight

NSCLC treated with EGFR inhibitors – EGFR Resisters

Photo: depositphotos.com

Jan 30, 2025, 06:15

NSCLC treated with EGFR inhibitors – EGFR Resisters

EGFR Resisters shared a post on X about a recent paper by Otto Manninen et al. published in Oncology:

“NSCLC treated with EGFR inhibitors: the effect of concurrent medications on patient outcomes

‘Conclusions: Among EGFR-TKI-treated NSCLC, the use of TCN, TCS, and DARD can affect treatment outcomes that should be considered in optimal patient care.’ ”

“Non-small cell lung cancer treated with epidermal growth factor receptor inhibitors: the effect of concurrent medications on patient outcomes”

Authors: Otto Manninen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen.

NSCLC treated with EGFR inhibitors - EGFR Resisters

More posts featuring EGFR Resisters.

cancer EGFR inhibitors EGFR Resisters Jussi Pekka Koivunen Martti Arffman non small cell lung cancer NSCLC OncoDaily Oncology Otto Manninen Sanna Iivanainen

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC

Hesham ElGhazaly: Global Inclusion in Clinical Trials at Vision Europe 2025

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

Arnaud Lallouette: Servier and IDEAYA Partner to Bring a Promising Uveal Melanoma Treatment

100 Oncologists, One Community: Reflections from the First ESO College Convention